| Trial ID: | L3794 |
| Source ID: | NCT00627744
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction
|
| Acronym: |
BEGAMI
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Myocardial Infarction|Unstable Angina Pectoris|Diabetes Mellitus|Impaired Glucose Tolerance
|
| Interventions: |
DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: Improvement in beta-cell function measured by means of the insulinogenic index (ΔI30/ΔG30) obtained from an oral glucose tolerance test (OGTT), By the end of the study as stated | Secondary: Improvement of glucose tolerance by means of an OGTT, As stated for the study|Improvement in endothelial function, As stated for the study|Improvement in incretin-independent beta-cell function measured as the Acute Insulin Response (ΔAIRG) during an intravenous glucose tolerance test., As stated for the study
|
| Sponsor/Collaborators: |
Sponsor: Karolinska Institutet
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
85
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-05
|
| Completion Date: |
2010-11
|
| Results First Posted: |
|
| Last Update Posted: |
2021-02-12
|
| Locations: |
Karolinska Institutet, Stockholm, 171 76, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT00627744
|
